Xiaobo Wang

Xiaobo Wang

Auto-generated profile, based on publicly available information

Xiaobo Wang

Cancer Research Institute School of Basic Medical Sciences State Key Laboratory of Multi‐organ Injury Prevention and Treatment Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy Southern Medical University Guangzhou 510515 China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in eLife
Verified
Journal Article
Open access
XWXiaobo Wang
Xiaobo Wang
MEMary Ellenbecker
Mary Ellenbecker
BHBenjamin Hickey
Benjamin Hickey
NDNicholas J Day
Nicholas J Day
EOEmily Osterli
Emily Osterli
EVEkaterina Voronina
Ekaterina Voronina
Stem cells support tissue maintenance, but the mechanisms that coordinate the rate of stem cell self-renewal with differentiation at a population level remain uncharacterized. We find that two PUF family RNA-binding proteins FBF-1 and FBF-2 have opposite effects onCaenorhabditis elegansgermline stem cell dynamics: FBF-1 restricts the rate of meiotic entry, while FBF-2 promotes both cell division and meiotic entry rates. Antagonistic effects of FBFs are mediated by their distinct activities toward the shared set of target mRNAs, where FBF-1-mediated post-transcriptional control requires the activity of CCR4-NOT deadenylase, while FBF-2 is deadenylase-independent and might protect the targets from deadenylation. These regulatory differences depend on protein sequences outside of the conserved PUF family RNA-binding domain. We propose that the opposing FBF-1 and FBF-2 activities serve to modulate stem cell division rate simultaneously with the rate of meiotic entry.

12 July 2023 in Experimental Dermatology
Verified
Journal Article
Open access
LYLiyan Yuan
Liyan Yuan
SCShijun Chen
Shijun Chen
KDKe Ding
Ke Ding
XWXiaobo Wang
Xiaobo Wang
WLWeiqi Lv
Weiqi Lv
THTao Huang
Tao Huang
Psoriasis is a chronic inflammatory skin disorder. The mechanism of psoriasis pathogenesis is not entirely clear. Here, we reported that the level of the N6‐methyladenosine (m 6 A) modification was increased in psoriatic CD4 + T cells compared with healthy controls. In the psoriasis mouse model, depletion of the RNA demethylase, Alkbh5, from CD4 + T cells promoted the psoriasis‐like phenotype and inflammation. Intriguingly, this phenotype and inflammation were alleviated by the ablation of the m 6 A methyltransferase Mettl3 in CD4 + T cells. Mechanistically, we found that the m 6 A modification of IL17A mRNA increased the expression of IL‐17A (an important pro‐inflammatory factor in psoriasis) and promoted psoriasis. Thus, our study provided evidence that the m 6 A modification of IL17A in CD4 + T cells regulates inflammation in psoriasis.

18 July 2025 in Advanced Science
Verified
Journal Article
Open access
THTao Huang
Tao Huang
SCShijun Chen
Shijun Chen
KDKe Ding
Ke Ding
LYLiyan Yuan
Liyan Yuan
WLWeiqi Lv
Weiqi Lv
ZRZhili Rong
Zhili Rong
Impaired N6‐methyladenosine (m 6 A) modification has been implicated in regulating various inflammatory diseases, but its role in psoriasis remains unclear. Here, m 6 A modification and its methyltransferase METTL3 are revealed to be upregulated in psoriatic macrophages, while the demethylase ALKBH5 is downregulated. Conditional knockout of Mettl3 in macrophages alleviated psoriasis‐like symptoms in mice, whereas knockout of Alkbh5 exacerbated them. Both in vivo and in vitro, Mettl3 deficiency inhibited IMQ‐induced M1 macrophage polarization, while Alkbh5 deficiency promoted M1 polarization. The regulation of macrophage polarization by m 6 A is likely mediated by targeting Slc15a3 . SLC15A3 enhances the recruitment of TASL, a recently identified endolysosomal IRF5 adaptor, which functions similarly to the IRF3 adaptors STING and MAVS at the endoplasmic reticulum (ER) and mitochondria, respectively, to augment IRF5 signaling via SLC15A4. The findings underscore the critical role of m 6 A RNA modification in psoriasis pathogenesis and unveil a novel regulatory mechanism of TASL‐IRF5 signaling through m 6 A modification, suggesting potential new therapeutic targets for psoriasis treatment.